Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3700-3711

  Cho, Ki Joon ^a,b,c   Schepens, Bert ^b,c   Seok, Jong Hyeon ^a   Kim, Sella ^a   Roose, Kenny ^b,c   Lee, Ji Hye ^a   Gallardo, Rodrigo ^b,d   Van Hamme, Evelien ^b,c   Schymkowitz, Joost ^b,d   Rousseau, Frederic ^b,d   Fiers, Walter ^b,c   Saelens, Xavier ^b,c   Kim, Kyung Hyun ^a  

^a Korea University   (South Korea)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M2E; TRYPTOPHAN; UNCLASSIFIED DRUG; VIRUS PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; PROTEIN BINDING; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; X RAY CRYSTALLOGRAPHY;

INFLUENZA A VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CRYSTALLOGRAPHY, X-RAY; IMMUNOGLOBULIN FAB FRAGMENTS; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN CONFORMATION; VIRAL MATRIX PROTEINS;

EID: 84924769564     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02576-14     Document Type: Article

References (57)

1. Lamb RA, Zebedee SL, Richardson CD. 1985. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627-633. http://dx.doi.org/10.1016/0092-8674(85)90211-9.
2. Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, Soto CS, Tereshko V, Nanda V, Stayrook S, DeGrado WF. 2008. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451:596-599. http://dx.doi.org/10.1038/nature06528.
3. Pinto LH, Dieckmann GR, Gandhi CS, Papworth CG, Braman J, Shaughnessy MA, Lear JD, Lamb RA, DeGrado WF. 1997. A functionally defined model for theM2proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc Natl Acad Sci USA 94:11301-11306. http://dx.doi.org/10.1073/pnas.94.21.11301.
4. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. 2010. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463:689-692. http://dx.doi.org/10.1038/nature08722.
5. Schnell JR, Chou JJ. 2008. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451:591-595. http://dx.doi.org/10.1038/nature06531.
6. Bukrinskaya AG, Vorkunova NK, Pushkarskaya NL. 1982. Uncoating of a rimantadine-resistant variant of influenza virus in the presence of rimantadine. J Gen Virol 60:61-66. http://dx.doi.org/10.1099/0022-1317-60-1-61.
7. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021-3024.
8. Gannage M, Dormann D, Albrecht R, Dengjel J, Torossi T, Ramer PC, Lee M, Strowig T, Arrey F, Conenello G, Pypaert M, Andersen J, Garcia-Sastre A, Munz C. 2009. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 6:367-380. http://dx.doi.org/10.1016/j.chom.2009.09.005.
9. Beale R, Wise H, Stuart A, Ravenhill BJ, Digard P, Randow F. 2014. A LC3-interacting motif in the influenza A virus M2 protein is required to subvert autophagy and maintain virion stability. Cell Host Microbe 15: 239-247. http://dx.doi.org/10.1016/j.chom.2014.01.006.
10. Schotsaert M, De Filette M, Fiers W, Saelens X. 2009. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8:499-508. http://dx.doi.org/10.1586/erv.09.6.
11. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163. http://dx.doi.org/10.1038/13484.
12. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003. http://dx.doi.org/10.1016/j.vaccine.2004.02.021.
13. Kitikoon P, Vincent AL, Janke BH, Erickson B, Strait EL, Yu S, Gramer MR, Thacker EL. 2009. Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates. Vaccine 28:523-531. http://dx.doi.org/10.1016/j.vaccine.2009.09.130.
14. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-5152. http://dx.doi.org/10.1016/j.vaccine.2011.05.041.
15. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K, for the Influenza Serology Working Group. 2014. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis 209:986-994. http://dx.doi.org/10.1093/infdis/jit811.
16. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20:143-151. http://dx.doi.org/10.1038/nm.3443.
17. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186:1022-1031. http://dx.doi.org/10.4049/jimmunol.0902147.
18. Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, Muntwiler S, Renner WA, Saudan P, Bachmann MF. 2009. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 6:224. http://dx.doi.org/10.1186/1743-422X-6-224.
19. Grandea AG, III, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad SciUS A 107:12658-12663. http://dx.doi.org/10.1073/pnas.0911806107.
20. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64:1375-1377.
21. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S. 2008. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80:168-177. http://dx.doi.org/10.1016/j.antiviral.2008.06.002.
22. Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, Fredlund P, Swiderek KM. 3 October 2014. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J Infect Dis http://dx.doi.org/10.1093/infdis/jiu539.
23. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403-28409. http://dx.doi.org/10.1074/jbc.R110.129809.
24. Pielak RM, Chou JJ. 2010. Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel. Biochem Biophys Res Commun 401:58-63. http://dx.doi.org/10.1016/j.bbrc.2010.09.008.
25. Cross TA, Dong H, Sharma M, Busath DD, Zhou HX. 2012. M2 protein from influenza A: from multiple structures to biophysical and functional insights. Curr Opin Virol 2:128-133. http://dx.doi.org/10.1016/j.coviro.2012.01.005.
26. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. 2005. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79:6644-6654. http://dx.doi.org/10.1128/JVI.79.11.6644-6654.2005.
27. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-11387. http://dx.doi.org/10.1074/jbc.M800650200.
28. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X.
29. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystall 67:235-242. http://dx.doi.org/10.1107/S0907444910045749.
30. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta CrystallogrDBiol Crystall 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158.
31. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. 2011. A graphical interface for the FoldX forcefield. Bioinformatics 27:1711-1712. http://dx.doi.org/10.1093/bioinformatics/btr254.
32. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. 2002. Eightplasmid system for rapid generation of influenza virus vaccines. Vaccine 20:3165-3170. http://dx.doi.org/10.1016/S0264-410X(02)00268-2.
33. Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X. 2012. Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J Virol 86:13445-13455. http://dx.doi.org/10.1128/JVI.01682-12.
34. De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, Fiers W, Saelens X. 2013. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol 87:3314-3323. http://dx.doi.org/10.1128/JVI.03019-12.
35. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. 2010. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 17:248-250. http://dx.doi.org/10.1038/nsmb.1723.
36. Levy Y, Onuchic JN. 2004. Water and proteins: a love-hate relationship. Proc Natl Acad Sci USA 101:3325-3326. http://dx.doi.org/10.1073/pnas.0400157101.
37. Nakasako M. 2004. Water-protein interactions from high-resolution protein crystallography. Phil Trans R Soc Lond Ser B Biol Sci 359:1191-1204. http://dx.doi.org/10.1098/rstb.2004.1498.
38. Zhang M, Zharikova D, Mozdzanowska K, Otvos L, Gerhard W. 2006. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Mol Immunol 43:2195-2206. http://dx.doi.org/10.1016/j.molimm.2005.12.015.
39. Zebedee SL, Lamb RA. 1988. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection ofM2in virions. J Virol 62:2762-2772.
40. Scian M, Lin JC, Le Trong I, Makhatadze GI, Stenkamp RE, Andersen NH. 2012. Crystal andNMRstructures of a Trp-cage mini-protein benchmark for computational fold prediction. Proc Natl Acad Sci USA 109: 12521-12525. http://dx.doi.org/10.1073/pnas.1121421109.
41. Kong J, Yu S. 2007. Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim Biophys Sin 39:549-559. http://dx.doi.org/10.1111/j.1745-7270.2007.00320.x.
42. Caoili SE. 2012. On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity. Adv Bioinformatics 2012:346765. http://dx.doi.org/10.1155/2012/346765.
43. Ofran Y, Rost B. 2007. Protein-protein interaction hotspots carved into sequences. PLoS Comput Biol 3:e119. http://dx.doi.org/10.1371/journal.pcbi.0030119.
44. Liao SY, Fritzsching KJ, Hong M. 2013. Conformational analysis of the full-length M2 protein of the influenza a virus using solid-state NMR. Protein Sci 22:1623-1638. http://dx.doi.org/10.1002/pro.2368.
45. Arzt S, Baudin F, Barge A, Timmins P, Burmeister WP, Ruigrok RW. 2001. Combined results from solution studies on intact influenza virusM1 protein and from a new crystal form of its N-terminal domain show that M1 is an elongated monomer. Virology 279:439-446. http://dx.doi.org/10.1006/viro.2000.0727.
46. Campbell AP, Sykes BD, Norrby E, Assa-Munt N, Dyson HJ. 1996. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of theHIV-2envelope glycoprotein gp125. Fold Des 1:157-165. http://dx.doi.org/10.1016/S1359-0278(96)00024-7.
47. Molins MA, Contreras MA, Fita I, Pons M. 1998. Solution conformation of an immunogenic peptide from HRV2: comparison with the conformation found in a complex with a Fab fragment of an anti-HRV2 neutralizing antibody. J Pept Sci 4:101-110. http://dx.doi.org/10.1002/(SICI)1099-1387(199804)4:2<101::AID-PSC133>3.0.CO;2-C.
48. Serriere J, Dugua JM, Bossus M, Verrier B, Haser R, Gouet P, Guillon C. 2011. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography. J Mol Biol 405:33-42. http://dx.doi.org/10.1016/j.jmb.2010.10.033.
49. Dyson HJ, Wright PE. 1995. Antigenic peptides. FASEB J 9:37-42.
50. Wlodarski T, Zagrovic B. 2009. Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin. Proc Natl Acad SciUSA106:19346-19351. http://dx.doi.org/10.1073/pnas.0906966106.
51. Neidigh JW, Fesinmeyer RM, Andersen NH. 2002. Designing a 20-residue protein. Nat Struct Biol 9:425-430. http://dx.doi.org/10.1038/nsb798.
52. Wise HM, Hutchinson EC, Jagger BW, Stuart AD, Kang ZH, Robb N, Schwartzman LM, Kash JC, Fodor E, Firth AE, Gog JR, Taubenberger JK, Digard P. 2012. Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLoS Pathog 8:e1002998. http://dx.doi.org/10.1371/journal.ppat.1002998.
53. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 109:4269-4274. http://dx.doi.org/10.1073/pnas.1116200109.
54. Ye Z, Liu T, Offringa DP, McInnis J, Levandowski RA. 1999. Association of influenza virus matrix protein with ribonucleoproteins. J Virol 73:7467-7473.
55. Bourmakina SV, Garcia-Sastre A. 2003. Reverse genetics studies on the filamentous morphology of influenza A virus. J Gen Virol 84:517-527. http://dx.doi.org/10.1099/vir.0.18803-0.
56. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X. 2009. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385:218-226. http://dx.doi.org/10.1016/j.virol.2008.11.035.
57. Lovell SC, Davis IW, Arendall WB, III, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. 2003. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 50:437-450. http://dx.doi.org/10.1002/prot.10286.